|
Sequencing in metastatic castrate-resistant prostate cancer with enzalutamide in a post-chemotherapy setting. |
|
|
Employment - Cardinal Health |
|
|
Employment - Astellas Pharma |
|
|
Employment - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Cardinal Health |
|
|
Employment - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
|
|
|
No Relationships to Disclose |